Ke Ding, Ph.D
Affiliations: | 1991-1998 | China Pharmaceutical University | |
| 1998-2001 | Fudan university, Shanghai, Shanghai Shi, China | ||
| 2006-2016 | Guangzhou Institutes Biomedicine and Health,CAS | ||
| 2016- | Jinan University |
Google:
"Ke Ding"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Fengtao Zhou | grad student | 2008-2013 | University of Chinese Academy of Sciences |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yang J, Chang Y, Zhou K, et al. (2025) Discovery of : A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition. Journal of Medicinal Chemistry |
| Yang B, Xun Q, Tian Y, et al. (2025) Discovery of BW710 as a potent, selective and orally bioavailable fibroblast growth factor receptor 2 (FGFR2) inhibitor. European Journal of Medicinal Chemistry. 287: 117339 |
| Li C, Chen Y, Huang W, et al. (2024) Structure-Based Design of "Head-to-Tail" Macrocyclic PROTACs. Jacs Au. 4: 4866-4882 |
| Wen C, Gajjala PR, Liu Y, et al. (2024) Discovery of the first selective and potent PROTAC degrader for the pseudokinase TRIB2. European Journal of Medicinal Chemistry. 281: 117016 |
| Zhou L, Zhou K, Chang Y, et al. (2024) Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader. Journal of Medicinal Chemistry |
| Zhang H, Lin G, Jia S, et al. (2024) Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors. Bioorganic Chemistry. 148: 107456 |
| Liu L, Zhao L, Yang L, et al. (2024) Discovery of as an Autophagy-Tethering Compound for the Degradation of Discoidin Domain Receptor 1. Journal of Medicinal Chemistry |
| Li H, Ke R, Zhou Y, et al. (2024) Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor. European Journal of Medicinal Chemistry. 272: 116473 |
| Liu L, Parolia A, Liu Y, et al. (2024) Discovery of LLC0424 as a Potent and Selective NSD2 PROTAC Degrader. Journal of Medicinal Chemistry |
| Niu P, Tao Y, Lin G, et al. (2024) Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors. Journal of Medicinal Chemistry |